Riskpilot← Back to searchSign inGet full accessPHARMAQ AS
ASActiveOrg 886953402Skogmo Industriområde Industrivegen 50, 7863 OverhallaManufacture of pharmaceutical preparations · NACE 2120Est. 2004300 employeeswww.pharmaq.no
Revenue 2024
NOK 2B
-7% vs 2023
EBITDA margin
59.6%
-12% vs 2023
Equity ratio
89.4%
Financial strength
Net profit 2024
NOK 949M
-12% vs 2023
| Revenue | NOK 2B | -7% |
| EBITDA | NOK 1,2B | -12% |
| Net profit | NOK 949M | -12% |
| Total assets | NOK 5B | +25% |
| Equity | NOK 4,5B | +27% |
| Employees | 300 | — |
Legal name
PHARMAQ AS
Org number
886953402
Legal form
Aksjeselskap
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
24. juni 2004
Share capital
NOK 17 166 700
Employees
300 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Trine astrid vatle
Company purpose
Produksjon og salg av veterinærfarmasøytiske produkter, handel, ervervelse og drift av faste eiendommer og utnyttelse av naturforekomster, finansieringsvirksomhet, samt annen virksomhet i forbindelse med slike formål. Selskapet kan ved aksjetegning eller på annen måte, herunder ved långivning, interessere seg i andre foretagender med samme eller lignende formål.
Address
Skogmo Industriområde Industrivegen 50, 7863 Overhalla
Phone
+4723298500
Email
customer.service
Website
www.pharmaq.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 448 282 | 569 790 | 612 338 | 673 547 | 731 751 | 934 739 | 1 103 647 | 1 187 450 | 1 264 115 | 1 568 977 | 2 179 986 | 2 017 487 |
| Staff expenses | −106 766 | −137 113 | −171 574 | −166 794 | −175 121 | −215 267 | −237 096 | −248 014 | −252 634 | −277 903 | −295 418 | −370 833 |
| EBITDA | 124 151 | 136 534 | 138 435 | 264 703 | 267 461 | 386 969 | 580 727 | 610 673 | 616 316 | 878 779 | 1 362 916 | 1 203 062 |
| Depreciation & amort. | −20 091 | −17 275 | −20 638 | −24 545 | −22 911 | −23 314 | −25 717 | −35 695 | −37 019 | −38 508 | −41 725 | −47 022 |
| EBIT | 104 060 | 119 259 | 117 797 | 240 158 | 244 550 | 363 655 | 555 010 | 574 978 | 579 297 | 840 271 | 1 321 191 | 1 156 040 |
| Net financials | −422 | 9 056 | 23 577 | −3 873 | −8 782 | 5 595 | −10 565 | 37 002 | −35 277 | −67 615 | 59 846 | 71 325 |
| Profit before tax | 103 638 | 128 315 | 141 374 | 236 285 | 235 768 | 369 250 | 544 445 | 611 979 | 544 020 | 772 656 | 1 381 036 | 1 227 365 |
| Tax | 28 355 | 34 089 | 23 869 | 59 507 | 55 633 | 82 290 | 119 012 | 133 334 | 121 465 | 186 711 | 303 022 | 278 362 |
| Net profit | 75 284 | 94 226 | 117 505 | 176 778 | 180 135 | 286 960 | 425 433 | 478 645 | 422 555 | 585 945 | 1 078 014 | 949 003 |
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 493 589 | 567 699 | 633 642 | 824 730 | 813 696 | 935 293 | 1 252 424 | 1 749 035 | 2 149 577 | 2 834 967 | 3 995 280 | 4 993 092 |
| Equity | 97 218 | 103 138 | 100 775 | 98 912 | 260 346 | 522 585 | 947 067 | 1 443 897 | 1 863 022 | 2 443 513 | 3 521 526 | 4 465 808 |
| Long-term debt | 116 176 | 117 047 | 284 486 | 479 626 | 388 459 | 10 993 | 7 000 | 15 604 | 9 770 | 883 | 8 143 | 43 134 |
| Short-term debt | 279 899 | 347 514 | 248 381 | 245 651 | 164 150 | 401 715 | 298 357 | 289 535 | 276 785 | 390 571 | 465 611 | 484 151 |
| Total debt | 396 075 | 464 561 | 532 867 | 725 277 | 552 609 | 412 708 | 305 357 | 305 139 | 286 555 | 391 454 | 473 754 | 527 285 |
EBITDA margin
59.6%
This company
15.8%
Market median
+277% vs market
20132024
Equity ratio
89.4%
This company
38.2%
Market median
+134% vs market
20132024
Return on equity
21.3%
This company
18.4%
Market median
+16% vs market
20132024
Net profit margin
47.0%
This company
8.1%
Market median
+480% vs market
20132024
Asset turnover
0.40×
This company
1.12×
Market median
-64% vs market
20132024
Debt / equity
0.12×
This company
0.62×
Market median
+81% vs market
20132024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via Brønnøysundsregistrene · Period 2013-01-01 – 2013-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
EM Deputy Member | Deputy Member | 2016 | — | — |
BM Chief Executive Officer | Chief Executive Officer | 2021 | — | — |
BF Deputy Member | Deputy Member | 2021 | — | — |
MK Chief Executive Officer | Chief Executive Officer | 2004 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2021 | — | — | |
| Chairman | 2021 | — | — | |
| Board of Directors | 2016 | — | — | |
| Chairman | 2016 | — | — | |
| Board of Directors | 2021 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Zoetis Netherlands 3 B.V. | Company | 100.0% | 100.0% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
PHARMAQ AS 
Pharmaq Fishteq AsBoard members of PHARMAQ AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Elin Marie Aksnes | Deputy Member | 0 companies |
| Bernt Martinsen | Chief Executive Officer | 0 companies |
| Børre Furulund | Deputy Member | 0 companies |
| Morten Kristoffer Nordstad | Chief Executive Officer | 0 companies |
| Nils Arne Grønlie | Board of Directors | 0 companies |
| Sissel Hansen | Board of Directors | 0 companies |
| Ben Backmann | Chairman | 0 companies |
| Anne Berit Romstad | Board of Directors | 0 companies |
| Carl Johan Vilhelm Ehn | Chairman | 0 companies |
| Marit Rode | Board of Directors | 0 companies |